Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Is nicotine protective against Parkinson's disease? An experimental analysis.

García-Montes JR, Boronat-García A, López-Colomé AM, Bargas J, Guerra-Crespo M, Drucker-Colín R.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):897-906.

PMID:
23131151
3.

Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.

Chaturvedi RK, Shukla S, Seth K, Chauhan S, Sinha C, Shukla Y, Agrawal AK.

Neurobiol Dis. 2006 May;22(2):421-34. Epub 2006 Feb 9.

PMID:
16480889
4.

Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.

Yuan H, Sarre S, Ebinger G, Michotte Y.

Brain Res. 2004 Nov 5;1026(1):95-107.

PMID:
15476701
5.

Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.

Salama M, Ellaithy A, Helmy B, El-Gamal M, Tantawy D, Mohamed M, Sheashaa H, Sobh M, Arias-Carrión O.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):836-43.

PMID:
23198691
6.

The distinct role of medium spiny neurons and cholinergic interneurons in the D₂/A₂A receptor interaction in the striatum: implications for Parkinson's disease.

Tozzi A, de Iure A, Di Filippo M, Tantucci M, Costa C, Borsini F, Ghiglieri V, Giampà C, Fusco FR, Picconi B, Calabresi P.

J Neurosci. 2011 Feb 2;31(5):1850-62. doi: 10.1523/JNEUROSCI.4082-10.2011.

7.
8.

Nicotine induces sensitization of turning behavior in 6-hydroxydopamine lesioned rats.

Gregório ML, Wietzikoski EC, Ferro MM, Silveira JL, Vital MA, Da Cunha C.

Neurotox Res. 2009 May;15(4):359-66. doi: 10.1007/s12640-009-9041-1. Epub 2009 Mar 18.

PMID:
19384569
9.

Effects of chronic, systemic treatment with the dopamine receptor agonist R-apomorphine in partially lesioned rat model of Parkinson's disease: an electrophysiological study of substantia nigra dopamine neurons.

Gui ZH, Liu J, Wang Y, Ali U, Wang T, Chen L.

Chin J Physiol. 2011 Apr 30;54(2):96-104. Erratum in: Chin J Physiol. 2011 Jun 30;54(3):203.

PMID:
21789890
10.

Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.

Doucet JP, Nakabeppu Y, Bedard PJ, Hope BT, Nestler EJ, Jasmin BJ, Chen JS, Iadarola MJ, St-Jean M, Wigle N, Blanchet P, Grondin R, Robertson GS.

Eur J Neurosci. 1996 Feb;8(2):365-81.

PMID:
8714707
11.

Neural stem cells transplanted in a mouse model of Parkinson's disease differentiate to neuronal phenotypes and reduce rotational deficit.

Ziavra D, Makri G, Giompres P, Taraviras S, Thomaidou D, Matsas R, Mitsacos A, Kouvelas ED.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):829-35.

PMID:
23131156
14.

Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.

Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM.

Neuroscience. 1995 Aug;67(3):631-47.

PMID:
7675192
15.

High frequency electro-acupuncture enhances striatum DAT and D1 receptor expression, but decreases D2 receptor level in 6-OHDA lesioned rats.

Rui G, Guangjian Z, Yong W, Jie F, Yanchao C, Xi J, Fen L.

Behav Brain Res. 2013 Jan 15;237:263-9. doi: 10.1016/j.bbr.2012.09.047. Epub 2012 Oct 2.

PMID:
23036843
16.
19.

Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions.

Altar CA, Boylan CB, Fritsche M, Jones BE, Jackson C, Wiegand SJ, Lindsay RM, Hyman C.

J Neurochem. 1994 Sep;63(3):1021-32.

PMID:
7519657

Supplemental Content

Support Center